Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 6/20 | 0.61 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652156 | 0.91 | GCK (0.66) | GCKFFAR2KCNH2SMN1; SMN2NPC1 | |
| SCHEMBL2650059 | 0.89 | GCK (0.66) | GCKFFAR2KCNH2SMN1; SMN2MEN1 | |
| SCHEMBL2654390 | 0.86 | GCK (0.66) | GCKFFAR2KCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2647322 | 0.85 | GCK (0.66) | GCKFFAR2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL2651139 | 0.84 | RAB9A (0.49) | KCNH2SMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL2650820 | 0.83 | RAB9A (0.57) | SMN1; SMN2NPC1TP53RAB9AALDH1A1 | |
| SCHEMBL2650556 | 0.82 | GCK (0.62) | GCKFFAR2KCNH2SMN1; SMN2NPC1 | |
| SCHEMBL27560127 | 0.82 | GCK (0.46) | GCKFFAR2SMN1; SMN2NPC1TP53 | |
| SCHEMBL2654951 | 0.81 | GCK (0.74) | GCKFFAR2KCNH2CYP1A2CYP3A4 | |
| SCHEMBL2664673 | 0.81 | GCK (0.74) | GCKFFAR2KCNH2SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283830-B1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | claimed |
| US-20030060625-A1 | Para-amine substituted phenylamide glucokinase activators | BIZZARRO FRED THOMAS (US) | 2003-03-27 | — | — | US | claimed |
| EP-1283830-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-19 | — | — | EP | claimed |
| US-20010051731-A1 | Para-amine substituted phenylamide glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-13 | — | — | US | claimed |
| WO-2001085707-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | claimed |
| EP-1283830-B1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1283830-B1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20030060625-A1 | Para-amine substituted phenylamide glucokinase activators | BIZZARRO FRED THOMAS (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1283830-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| US-6489485-B2 | INCREASES INSULIN SECRETION; TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-12-03 | — | — | US | disclosed |
| US-20010051731-A1 | Para-amine substituted phenylamide glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001085707-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085707-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051731-A1 | Para-amine substituted phenylamide glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885FFAR2 1016/4885KCNH2 478/4885 |
| US-20030060625-A1 | Para-amine substituted phenylamide glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885FFAR2 1016/4885KCNH2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.